Loading…
Alumis Inc Is A Clinical-Stage Biopharmaceutical Company With An Initial Focus On Developing Its Two Tyrosine Kinase 2 ("Tyk2") Inhibitors: Envudeucitinib ("Envu"), An Allosteric Tyk2 Inhibitor For The Treatment Of Pso And Sle; And A-005, A Central Nervous System ("Cns") Penetrant Allosteric Tyk2 Inhibitor, To Offer The Therapeutic Benefit Of Tyk2 Inhibition Within The Cns For A Broad Range Of Neuroinflammatory And Neurodegenerative Diseases.